Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Edesa Biotech, Inc. - Common Shares (NQ:EDSA)

0.8369 -0.0660 (-7.31%)
Streaming Delayed Price Updated: 2:03 PM EST, Feb 20, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Edesa Biotech, Inc. - Common Shares

< Previous 1 2 3 4 5 Next >
News headline image
Dow Tumbles 300 Points; Morgan Stanley Beats Q4 Views ↗
U.S. stocks traded mostly lower midway through trading, with the Dow Jones dropping over 300 points on Tuesday. 
Via Benzinga
News headline image
Dow Drops Over 150 Points; Goldman Sachs Profit Misses Expectations ↗
U.S. stocks traded lower this morning, with the Dow Jones dropping over 150 points on Tuesday. 
Via Benzinga
News headline image
Edesa Biotech Reports Topline Phase 2b Results for Dermatology Drug
Via ACCESSWIRE
News headline image
Why Applied Molecular Transport Shares Are Trading Lower By Over 55%? Here Are 47 Stocks Moving In Friday's Mid-Day Session ↗
Gainers 
Via Benzinga
News headline image
Edesa Biotech Adds Mechanically Ventilated Patients To Late-Stage COVID-19 Study ↗
 
Via Benzinga
News headline image
Why AMC Entertainment Shares Are Trading Lower By Around 13%? Here Are 59 Stocks Moving In Thursday's Mid-Day Session ↗
Gainers Core Scientific, Inc. (NASDAQ: CORZ) shares jumped 188% to $0.1471. Core Scientific shares dipped 75% on Wednesday after the company filed for Chapter 11 bankruptcy. 
Via Benzinga
News headline image
FDA Grants Fast Track to Edesa Biotech's ARDS Drug Candidate
Via ACCESSWIRE
News headline image
Edesa Biotech Reports Fiscal Year 2022 Results
Via ACCESSWIRE
News headline image
Edesa Biotech to Participate in the 2022 Cantor Fitzgerald Dermatology Conference
Via ACCESSWIRE
News headline image
Edesa Biotech Announces Closing of $3.0 Million Private Placement Priced At-the-Market
Via ACCESSWIRE
News headline image
What Is Going on With Edesa Biotech (EDSA) Stock Today? ↗
Edesa Biotech released encouraging Phase 2 results for its respiratory-syndrome-targeting antibody, thus initially boosting EDSA stock. 
Via InvestorPlace
News headline image
Edesa Biotech Reports Statistically Significant Mortality Reductions in Phase 2 ARDS Drug Study
Via ACCESSWIRE
News headline image
Why F45 Training Shares Climbed 41%; Here Are 84 Biggest Movers From Friday ↗
Gainers FingerMotion, Inc. (NASDAQ: FNGR) gained 82.2% to close at $3.37. 
Via Benzinga
News headline image
Edesa Biotech to Present at Upcoming H.C. Wainwright Investor Conference
Via ACCESSWIRE
News headline image
Edesa Biotech Reports Phase 2b Study Reaches Full Enrollment
Via ACCESSWIRE
News headline image
Edesa Biotech Reports Fiscal 3rd Quarter 2022 Results
Via ACCESSWIRE
News headline image
Edesa Biotech to Participate at the Upcoming BTIG Biotech Conference
Via ACCESSWIRE
News headline image
Edesa Biotech to Present at ARDS Drug Development Summit
TORONTO, ON / ACCESSWIRE / July 11, 2022 / Edesa Biotech, Inc. (Nasdaq:EDSA), a clinical-stage biopharmaceutical company focused on inflammatory and immune-related diseases, announced today that Par... 
From Edesa Biotech
Via AccessWire
News headline image
Stocks That Hit 52-Week Lows On Tuesday ↗
On Tuesday, 87 companies hit new 52-week lows. 
Via Benzinga
News headline image
Edesa Biotech Adds Mechanically Ventilated Patients to Phase 3 ARDS Study
TORONTO, ON / ACCESSWIRE / May 24, 2022 / Edesa Biotech, Inc. (Nasdaq:EDSA), a clinical-stage biopharmaceutical company focused on inflammatory and immune-related diseases, today announced that the... 
From Edesa Biotech
Via AccessWire
News headline image
Edesa Biotech to Present at H.C. Wainwright Global Investment Conference
TORONTO, ON / ACCESSWIRE / May 19, 2022 / Edesa Biotech, Inc. (NASDAQ:EDSA), a clinical-stage biopharmaceutical company focused on inflammatory and immune-related diseases, announced today that Par... 
From Edesa Biotech
Via AccessWire
News headline image
Edesa Biotech Reports Fiscal 2nd Quarter 2022 Results
TORONTO, ON / ACCESSWIRE / May 13, 2022 / Edesa Biotech, Inc. (NASDAQ:EDSA), a clinical-stage biopharmaceutical company focused on inflammatory and immune-related diseases, today reported financial... 
From Edesa Biotech
Via AccessWire
News headline image
Edesa Biotech Reports Dermatitis Study Enrolling Faster than Expected
Our newswire features a comprehensive, flat-fee Press Release service. Generate quality engagement with real-time analytics to improve visibility and expand your influence. 
From Edesa Biotech
Via AccessWire
News headline image
Edesa Biotech Appoints Strategy Expert to Board of Directors
TORONTO, ON / ACCESSWIRE / March 29, 2022 / Edesa Biotech, Inc. (NASDAQ:EDSA), a clinical-stage biopharmaceutical company focused on inflammatory and immune-related diseases, today announced the... 
From Edesa Biotech
Via AccessWire
News headline image
Edesa Biotech Announces Closing of $10.0 Million Registered Direct Offering
TORONTO, ON / ACCESSWIRE / March 24, 2022 / Edesa Biotech, Inc. (NASDAQ:EDSA), a clinical-stage biopharmaceutical company focused on inflammatory and immune-related diseases, today announced the... 
From Edesa Biotech
Via AccessWire
News headline image
66 Biggest Movers From Yesterday ↗
Gainers JX Luxventure Limited (NASDAQ: LLL) shares jumped 119.5% to settle at $4.39 on Tuesday after the company announced it signed a $60 million sales agreement. Forge Global... 
Via Benzinga
News headline image
Edesa Biotech Announces $10.0 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules
TORONTO, ON / ACCESSWIRE / March 22, 2022 / Edesa Biotech, Inc. (NASDAQ:EDSA), a clinical-stage biopharmaceutical company focused on inflammatory and immune-related diseases, today announced that it... 
From Edesa Biotech
Via AccessWire
News headline image
Edesa Biotech Reports Enrollment Milestone in Phase 3 ARDS Study
TORONTO, ON / ACCESSWIRE / February 17, 2022 / Edesa Biotech, Inc. (NASDAQ:EDSA), a clinical-stage biopharmaceutical company focused on inflammatory and immune-related diseases, today provided an... 
From Edesa Biotech
Via AccessWire
News headline image
Edesa Biotech Reports Fiscal 1st Quarter 2022 Results
TORONTO, ON / ACCESSWIRE / February 14, 2022 / Edesa Biotech, Inc. (NASDAQ:EDSA), a clinical-stage biopharmaceutical company focused on inflammatory and immune-related diseases, today reported... 
From Edesa Biotech
Via AccessWire
News headline image
Edesa Biotech to Join Ontario Bioscience Panel Discussion
TORONTO, ON / ACCESSWIRE / January 26, 2022 / Edesa Biotech, Inc. (NASDAQ:EDSA), a clinical-stage biopharmaceutical company focused on inflammatory and immune-related diseases, announced today that Dr.... 
From Edesa Biotech
Via AccessWire
< Previous 1 2 3 4 5 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.